Reckitt Benckiser Group (LON:RB) received a GBX 9,000 ($117.60) price objective from JPMorgan Chase & Co. in a research note issued on Thursday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 36.47% from the stock’s previous close.

A number of other equities analysts also recently commented on the stock. UBS Group downgraded shares of Telstra from a “buy” rating to a “neutral” rating in a research note on Monday, July 1st. Goldman Sachs Group set a GBX 6,870 ($89.77) target price on shares of Reckitt Benckiser Group and gave the company a “neutral” rating in a research note on Tuesday, June 25th. Deutsche Bank reissued a “hold” rating and issued a GBX 1,775 ($23.19) target price on shares of in a research note on Wednesday, June 26th. Royal Bank of Canada downgraded shares of 3M from an “outperform” rating to a “sector perform” rating and dropped their price target for the stock from $207.00 to $176.00 in a research note on Monday, July 8th. Finally, Liberum Capital lifted their price target on shares of Moneysupermarket.Com Group from GBX 520 ($6.79) and gave the stock a “buy” rating in a research note on Thursday. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have issued a buy rating to the company’s stock. Reckitt Benckiser Group currently has an average rating of “Hold” and a consensus price target of GBX 7,211.11 ($94.23).

Shares of RB stock opened at GBX 6,595 ($86.18) on Thursday. The company has a fifty day simple moving average of GBX 6,384.22. Reckitt Benckiser Group has a 52 week low of GBX 5,559 ($72.64) and a 52 week high of GBX 7,174 ($93.74). The company has a debt-to-equity ratio of 80.49, a quick ratio of 0.47 and a current ratio of 0.65. The stock has a market cap of $46.76 billion and a P/E ratio of 21.64.

In other Reckitt Benckiser Group news, insider Andrew R. J. Bonfield purchased 146 shares of the firm’s stock in a transaction dated Tuesday, May 21st. The stock was acquired at an average cost of GBX 6,290 ($82.19) per share, with a total value of £9,183.40 ($11,999.74). Also, insider Christopher Sinclair purchased 1,076 shares of the firm’s stock in a transaction dated Thursday, May 23rd. The stock was acquired at an average cost of GBX 6,375 ($83.30) per share, with a total value of £68,595 ($89,631.52).

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands.

Featured Article: What are economic reports?

Analyst Recommendations for Reckitt Benckiser Group (LON:RB)

Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.